Cancer Immunotherapy News and Research

RSS

Breakthrough finding reveals how male sex hormones contribute to cancer-related sex bias

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes.

15 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Unique immune cell fingerprint can help rapidly identify better treatment for autoimmune disease

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

7 Apr 2022

Health and Social Care Secretary announces an extension on the cancer call for evidence to April 8

More people can share their experiences and views on how the country can lead the world on cancer care, as the Health and Social Care Secretary announces an extension on the cancer call for evidence to inform an ambitious 10-Year Cancer Plan.

1 Apr 2022

Magneto-activated natural killer cells for treating solid tumors

Cancer immunotherapy - a type of treatment that enlists our own immune cells to attack tumors - has revolutionized the way that many types of cancer are treated. One type of immunotherapy under investigation uses natural killer cells, a type of immune cell that can seek and destroy harmful cells.

28 Mar 2022

FDA approves new treatment for patients with metastatic melanoma based on Johns Hopkins research

The U.S. Food and Drug Administration has approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer.

23 Mar 2022

New approach radically increases the success of breast cancer immunotherapy

A study published in the journal Nature Cancer, carried out within the Cancer Programme at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) by the Cancer Stem Cells and Metastasis Dynamics Laboratory, led by Dr. Toni Celià-Terrassa, and the Laboratory of Molecular Cancer Therapy, coordinated by Dr. Joan Albanell, with the participation of international centers, has discovered an approach that radically increases the success of immunotherapy in one of the most aggressive types of tumors, triple-negative breast cancer.

17 Mar 2022

Novel metabolic mechanisms contribute to how ovarian cancer evades immune attack, research finds

High-grade serous carcinoma is the most aggressive form of ovarian cancer and accounts for the majority of advanced-stage cases.

16 Mar 2022

Novel approach to generate reliable breast tumor models may pave way for better immunotherapies

The discrepancy between preclinical advances in breast cancer immunotherapy and poor patient outcomes is rooted in the limitations of current breast cancer models. These models often fail to mimic complex interactions between cancer cells and key immune cells present in the tumor microenvironment.

3 Mar 2022

Adding immunotherapy drug to standard head and neck cancer treatment increases patient survival

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

1 Mar 2022

Microorganisms hindering cancer therapy have more influence than the beneficial ones, study says

Melanoma patients receiving therapy that helps their immune system kill cancer cells respond to treatment differently depending on the types of microbes in their gut, and new research suggests the microorganisms hindering therapy have more influence than the beneficial ones.

28 Feb 2022

Understanding the gut microbiome could help personalize immunotherapy for melanoma

The largest study to date has confirmed the link between the gut microbiome and the response to cancer immunotherapy therapy for melanoma.

28 Feb 2022

Researchers develop new precision medicine technology for cancer immunotherapy

In recent years, great advances have been made in the development of new successful immunotherapies to treat cancer. CAR T-cell therapy and antibody treatments are two types of targeted immunotherapies that have revolutionized areas of cancer care.

28 Feb 2022

LJI researchers discover new genes in CD4+ "helper" T cell subsets

T cells play important roles in helping to fight infections and cancers - and they can also drive autoimmune diseases. Now researchers at La Jolla Institute for Immunology (LJI) have discovered new genes in CD4+ "helper" T cell subset that are linked to risk of autoimmune diseases.

25 Feb 2022

MAIT cells exercise complex functions and may be targets for future immunotherapies and vaccines

A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells, an unconventional form of immune cell, exercise several complex roles during healthy and disease states.

24 Feb 2022

Developing nanoplatforms for direct drug delivery to T cells

T cells, also known as lymphocytes, have important roles in various immune reactions. However, there are only a few reports on delivery systems into T cells. Realizing this, it is essential to work and actively contribute in controlling immune systems.

16 Feb 2022

Cancer Immunotherapy News and Research

Breakthrough finding reveals how male sex hormones contribute to cancer-related sex bias

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

Unique immune cell fingerprint can help rapidly identify better treatment for autoimmune disease

Health and Social Care Secretary announces an extension on the cancer call for evidence to April 8

Magneto-activated natural killer cells for treating solid tumors

FDA approves new treatment for patients with metastatic melanoma based on Johns Hopkins research

New approach radically increases the success of breast cancer immunotherapy

Novel metabolic mechanisms contribute to how ovarian cancer evades immune attack, research finds

Novel approach to generate reliable breast tumor models may pave way for better immunotherapies

Adding immunotherapy drug to standard head and neck cancer treatment increases patient survival

Microorganisms hindering cancer therapy have more influence than the beneficial ones, study says

Understanding the gut microbiome could help personalize immunotherapy for melanoma

Researchers develop new precision medicine technology for cancer immunotherapy

LJI researchers discover new genes in CD4+ "helper" T cell subsets

MAIT cells exercise complex functions and may be targets for future immunotherapies and vaccines

Developing nanoplatforms for direct drug delivery to T cells

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

CRISPRa method helps discover genes that play a role in immune cell biology

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News